.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Farmers Insurance
Cantor Fitzgerald
Boehringer Ingelheim
Moodys
Johnson and Johnson
McKinsey
Chubb
Colorcon
QuintilesIMS

Generated: September 26, 2017

DrugPatentWatch Database Preview

Daiichi Sankyo Company Profile

« Back to Dashboard

What is the competitive landscape for DAIICHI SANKYO, and when can generic versions of DAIICHI SANKYO drugs launch?

DAIICHI SANKYO has eleven approved drugs.

There are five US patents protecting DAIICHI SANKYO drugs.

There are two hundred and fifty-nine patent family members on DAIICHI SANKYO drugs in thirty-six countries.

Summary for Applicant: Daiichi Sankyo

Patents:5
Tradenames:9
Ingredients:9
NDAs:11
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo
BENICAR HCT
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL021532-003Jun 5, 2003ABRXYesNo► Subscribe► Subscribe ► Subscribe
Daiichi Sankyo
BENICAR
olmesartan medoxomil
TABLET;ORAL021286-001Apr 25, 2002ABRXYesNo► Subscribe► Subscribe ► Subscribe
Daiichi Sankyo
TRIBENZOR
amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL200175-002Jul 23, 2010ABRXYesNo► Subscribe► Subscribe ► Subscribe
Daiichi Sankyo Inc
MORPHABOND ER
morphine sulfate
TABLET, EXTENDED RELEASE;ORAL206544-001Oct 2, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo Inc
ROXYBOND
oxycodone hydrochloride
TABLET;ORAL209777-002Apr 20, 2017RXNoNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo
WELCHOL
colesevelam hydrochloride
FOR SUSPENSION;ORAL022362-002Oct 2, 2009RXYesYes► Subscribe► SubscribeY► Subscribe
Daiichi Sankyo Inc
MORPHABOND ER
morphine sulfate
TABLET, EXTENDED RELEASE;ORAL206544-003Oct 2, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Daiichi Sankyo
BENICAR HCT
hydrochlorothiazide; olmesartan medoxomil
TABLET;ORAL021532-002Jun 5, 2003ABRXYesNo► Subscribe► Subscribe ► Subscribe
Daiichi Sankyo Inc
SAVAYSA
edoxaban tosylate
TABLET;ORAL206316-001Jan 8, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Daiichi Sankyo
AZOR
amlodipine besylate; olmesartan medoxomil
TABLET;ORAL022100-001Sep 26, 2007ABRXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Daiichi Sankyo

Paragraph IV activity for DAIICHI SANKYO drugs

Drugname Dosage Strength Tradename Submissiondate
colesevelam hydrochloride
Powder for Oral Suspension1.875 g/Packet and 3.75 g/Packet
WELCHOL
4/9/2010
colesevelam hydrochloride
Tablets625 mg
WELCHOL
7/1/2009
cevimeline hydrochloride
Capsules30 mg
EVOXAC
2/27/2009
amlodipine besylate and olmesartan medoxomil
Tablets10 mg/20 mg and 5 mg/40 mg
AZOR
3/31/2008
amlodipine besylate and olmesartan medoxomil
Tablets5 mg/20 mg and 10 mg/40 mg
AZOR
2/11/2008
olmesartan medoxomil and hydrochlorothiazide
Tablets20 mg/12.5 mg
BENICAR HCT
5/11/2007
olmesartan medoxomil and hydrochlorothiazide
Tablets40 mg/12.5 mg and 40 mg/25 mL
BENICAR HCT
2/15/2007
olmesartan medoxomil
Tablets5 mg, 20 mg and 40 mg
BENICAR
4/25/2006

Non-Orange Book Patents for Daiichi Sankyo

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,646,171 Angiotensin II antagonist 1-biphenylmethylimidazole compounds and their therapeutic use► Subscribe
8,377,428Low salt forms of polyallylamine► Subscribe
7,541,024Low salt forms of polyallylamine► Subscribe
7,342,014Diamine derivatives► Subscribe
7,261,880Methods of treating Syndrome X with aliphatic polyamines► Subscribe
8,267,452Product gripper► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Daiichi Sankyo Drugs

Country Document Number Estimated Expiration
Australia647887► Subscribe
Poland398653► Subscribe
Japan3461863► Subscribe
World Intellectual Property Organization (WIPO)02085383► Subscribe
Denmark0545912► Subscribe
Ireland920540► Subscribe
European Patent Office2187873► Subscribe
Hungary9301600► Subscribe
JapanH0578328► Subscribe
Luxembourg91330► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Daiichi Sankyo Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00095Netherlands► SubscribePRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
835Luxembourg► SubscribePRODUCT NAME: EDOXABAN, UN DE SES SELS, UN DE SES SOLVATES OU UN N-OXYDE DE CELUI-CI, EN PARTICULIER UN TOSYLATE D EDOXABAN. FIRST REGISTRATION: 20150619
0760Netherlands► SubscribePRODUCT NAME: EDOBAXAN, EEN ZOUT DAARVAN, EEN SOLVAAT DAARVAAN OF EEN N-OXIDE DAARVAN, IN HET BIJZONDER EDOBAXAN TOSYLAAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
2015000077Germany► SubscribePRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
0503785/01Switzerland► SubscribeFORMER OWNER: SANKYO COMPANY LIMITED, JP
/2009Austria► SubscribePRODUCT NAME: KOMBINATION VON OLMESARTAN MEDOXOMIL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH AKZEPTABLEN SALZES, MIT AMLODIPINBESILAT; NAT. REGISTRATION NO/DATE: 1-27894, 1-27895, 1-27896 20081217; FIRST REGISTRATION: NL 100989, 100990, 100991 20080819
C0037France► SubscribePRODUCT NAME: OLMESARTAN MEDOXOMIL; NAT. REGISTRATION NO/DATE: NL28292 20030806; FIRST REGISTRATION: DE - 50202.00 20020813
315Luxembourg► SubscribePRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
00159Netherlands► SubscribePRODUCT NAME: COLESEVELAM, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/03/268/001 20040310
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Chinese Patent Office
UBS
Cipla
Cerilliant
Dow
Harvard Business School
Moodys
QuintilesIMS
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot